MapLight Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	55.71	46.73	38.25
Short-Term Investments	254.41	258.37	70.54
Cash & Short-Term Investments	310.11	305.1	108.8
Cash Growth	185.04%	180.44%	-
Other Current Assets	17.12	19.57	5.81
Total Current Assets	327.23	324.67	114.6
Net Property, Plant & Equipment	6.23	6.58	7.56
Long-Term Investments	85.09	147.99	11.38
Other Long-Term Assets	0.24	0.27	3.37
Total Assets	418.79	479.51	136.92
Accounts Payable	3.19	3.29	1.91
Accrued Expenses	10.18	12.05	9.99
Current Portion of Leases	0.92	0.89	0.78
Unearned Revenue	-	-	3.24
Total Current Liabilities	14.28	16.23	15.92
Long-Term Leases	4.67	4.91	5.8
Total Long-Term Liabilities	4.67	4.91	5.8
Total Liabilities	18.95	21.14	21.72
Common Stock	0.01	0.01	-
Additional Paid-in Capital	821.9	819.12	5.58
Accumulated Other Comprehensive Income	-0.88	-0.23	0.16
Retained Earnings	-421.19	-360.52	-199.37
Total Common Shareholders' Equity	399.83	458.37	-193.63
Minority Interest	-	-	308.82
Shareholders' Equity	399.83	458.37	115.2
Total Liabilities & Equity	418.79	479.51	136.92
Total Debt	5.59	5.8	6.58
Net Cash (Debt)	304.52	299.3	102.22
Net Cash Growth	1.74%	192.81%	-
Net Cash Per Share	15.42	34.48	138.85
Book Value	399.83	458.37	-193.63
Book Value Per Share	20.25	52.80	-263.02
Tangible Book Value	399.83	458.37	-193.63
Tangible Book Value Per Share	20.25	52.80	-263.02

SEC Filings: 10-K · 10-Q